This Magnificent Dividend Stock Continues to Deliver Powerful Growth
NextEra Energy delivered strong earnings growth in the second quarter, powered by robust renewable energy demand.
The company remains on track to deliver high-end earnings growth through 2027.
It should have plenty of power to continue growing beyond that time frame.
10 stocks we like better than NextEra Energy ›
NextEra Energy (NYSE: NEE) has done a magnificent job paying dividends over the years. The utility has raised its payout every year for more than three decades, growing it at a 10% compound annual rate since 2007.
The company should have plenty of power to continue increasing its nearly 3%-yielding dividend. That's evident from its strong second-quarter results and visible growth outlook.
Another quarter of powerful growth
"NextEra Energy delivered strong second-quarter results, with adjusted earnings per share increasing by 9.4% year over year," stated CEO John Ketchum in the second-quarter earnings press release. The company delivered robust operating and financial performance at both its electric utility (FPL) and energy resources segment.
FPL generated $1.3 billion ($0.62 per share) of net income in the second quarter, a 3.3% increase year over year. The Florida-based utility benefited from continued investment in its business, including $2 billion in capital spending during the second quarter. FPL is investing heavily to install solar panels to capitalize on the state's abundant sunshine.
NextEra's energy resources segment posted nearly $1.1 billion ($0.53 per share) of adjusted net income, rising more than 25% year over year. New investments in renewable energy helped drive growth during the quarter. Over the past three months, the company placed 1.1 gigawatts (GW) of new wind, solar, and storage capacity into service.
The powerful growth should continue
NextEra's strong second quarter gave it the confidence to reaffirm its long-term outlook. It still targets 6% to 8% annual adjusted earnings per share growth from 2024 through 2027. It also expects to deliver about 10% annual dividend growth through at least next year. Ketchum said he would be "disappointed" if the company's financial results did not meet or exceed the top end of its expectations through 2027 while maintaining its strong balance sheet and credit ratings.
Strong, growing demand for renewable energy underpins the company's confidence in its long-term growth outlook. NextEra's energy resources segment added 3.2 GW of new projects to its backlog during the second quarter, increasing it to nearly 30 GW of projects. That's a massive backlog, considering that this segment had 38 GW of operating capacity at the end of March.
Technology and data center customers are major drivers of renewable energy demand. NextEra's energy resources segment added more than 1 GW of projects in the second quarter to support growing power demand from large data center operators. It now has about 6 GW of projects underway tied to technology and data center customers.
When combined with its existing capacity serving this customer group, the company will eventually produce more than 10.5 GW of renewable power solely to support the technology sector. That's more than the generating capacity of many large power companies, and enough to support the energy needs of millions of U.S. homes.
NextEra's growth likely won't slow after 2027. Forecasters expect U.S. electricity demand to surge in the coming decades, accelerating significantly from the modest growth rate of the past couple of decades. As a leader in renewable energy development, NextEra Energy is in a strong position to capitalize on this surge. Few companies can match NextEra's combination of scale, expertise, and financial strength, which it can leverage to deliver the low-cost renewable power its customers need to support their growing energy demand.
A great dividend growth stock
NextEra Energy's earnings are growing rapidly, a trend that should continue in the coming years, driven by strong demand for renewable energy. The company's earnings growth should give it ample fuel to continue increasing its high-yield dividend. That compelling combination of growth and income makes NextEra look like an excellent stock to buy and hold for the long term.
Should you invest $1,000 in NextEra Energy right now?
Before you buy stock in NextEra Energy, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and NextEra Energy wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $641,800!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,023,813!*
Now, it's worth noting Stock Advisor's total average return is 1,034% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Matt DiLallo has positions in NextEra Energy. The Motley Fool has positions in and recommends NextEra Energy. The Motley Fool has a disclosure policy.
This Magnificent Dividend Stock Continues to Deliver Powerful Growth was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) ('Vaalco' or the 'Company') today announced the timing of its second quarter 2025 earnings release and conference call. The Company will issue its second quarter 2025 earnings release on Thursday, August 7, 2025 after the close of trading on the New York Stock Exchange and host a conference call to discuss its financial and operational results on Friday morning, August 8, 2025 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time and 3:00 p.m. London Time.) Interested parties in the United States may participate toll-free by dialing (833) 685-0907. Interested parties in the United Kingdom may participate toll-free by dialing 08082389064. Other international parties may dial (412) 317-5741. Participants should ask to be joined to the 'Vaalco Energy Earnings Conference Call.' This call will also be webcast on VAALCO's website at An audio replay will be available on the Company's website following the call. About Vaalco Vaalco, founded in 1985 and incorporated under the laws of Delaware, is a Houston, Texas, USA based, independent energy company with a diverse portfolio of production, development and exploration assets across Gabon, Egypt, Côte d'Ivoire, Equatorial Guinea, Nigeria and Canada. For Further Information Vaalco Energy, Inc. (General and Investor Enquiries) +00 1 713 543 3422 Website: Al Petrie Advisors (US Investor Relations) +00 1 713 543 3422 Al Petrie / Chris Delange Buchanan (UK Financial PR) +44 (0) 207 466 5000 Ben Romney / Barry Archer Vaalco@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data